CE-C4D method for determination of beta-secretase activity as a tool for unbiased screening of potential drugs for patients suffering from Alzheimer’s disease

Investor logo
Investor logo
Authors

MÁDR Aleš CELÁ Andrea SCHEJBAL Jan JUŘICA Jan ŘEMÍNEK Roman GLATZ Zdeněk

Year of publication 2017
Type Conference abstract
Citation
Attached files
Description Alzheimer‘s disease is the most common form of dementia with incidence that almost double every 20 years. It is a progressive disease, where dementia symptoms worsen over a number of years. Although current treatments cannot stop Alzheimer‘s from progressing, they can temporarily slow the worsening of the symptoms. One of the therapeutic targets is the inhibition of beta-secretase enzyme. Inhibition studies are conducted predominantly as a batch-wise screening using probes allowing FRET based determination of the enzyme activity. This approach, however, suffers from fluorescence quenching leading to biased results. As a result, a novel method based on capillary electrophoresis coupled with contactless conductivity detection was developed for separation and quantification of native form of substrate and its hydrolytic products.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.